Abstract
Alterations in gait and balance are manifest in numerous neurological disorders such as the ataxias and Parkinson's disease, and may occur as a consequence of stroke, traumatic brain injury and chemical insults to the brain. Although the underlying etiology of these disorders differs, disturbances in gait and balance appear to reflect deficits in cholinergic pathways within the brain. During the past 40 years, both clinical case studies and preclinical data have provided evidence that nicotinic cholinergic activation is beneficial for alleviating gait and balance deficits in many disorders. Further, studies indicate that activation of neuronal nicotinic receptors leads to neuroprotective and neurotrophic actions. And yet, despite these findings, there hsas been no concerted effort to develop neuronal nicotinic agonists for the treatment of abnormal gait and balance. The goal of this review is to shed light on the therapeutic benefit of the cholinergic nicotinic system for the treatment of ataxia, and discuss the challenges and limitations associated with developing drugs to treat disorders involving deficits in gait and balance.
Keywords: Ataxias, neuronal nicotinic receptor, varenicline, nicotine, gait, balance.
Current Pharmaceutical Design
Title:Regulation of Gait and Balance: The Underappreciated Role of Neuronal Nicotinic Receptor Agonists
Volume: 22 Issue: 14
Author(s): Michael F. Young and Lynn Wecker
Affiliation:
Keywords: Ataxias, neuronal nicotinic receptor, varenicline, nicotine, gait, balance.
Abstract: Alterations in gait and balance are manifest in numerous neurological disorders such as the ataxias and Parkinson's disease, and may occur as a consequence of stroke, traumatic brain injury and chemical insults to the brain. Although the underlying etiology of these disorders differs, disturbances in gait and balance appear to reflect deficits in cholinergic pathways within the brain. During the past 40 years, both clinical case studies and preclinical data have provided evidence that nicotinic cholinergic activation is beneficial for alleviating gait and balance deficits in many disorders. Further, studies indicate that activation of neuronal nicotinic receptors leads to neuroprotective and neurotrophic actions. And yet, despite these findings, there hsas been no concerted effort to develop neuronal nicotinic agonists for the treatment of abnormal gait and balance. The goal of this review is to shed light on the therapeutic benefit of the cholinergic nicotinic system for the treatment of ataxia, and discuss the challenges and limitations associated with developing drugs to treat disorders involving deficits in gait and balance.
Export Options
About this article
Cite this article as:
Young F. Michael and Wecker Lynn, Regulation of Gait and Balance: The Underappreciated Role of Neuronal Nicotinic Receptor Agonists, Current Pharmaceutical Design 2016; 22 (14) . https://dx.doi.org/10.2174/1381612822666160127111848
DOI https://dx.doi.org/10.2174/1381612822666160127111848 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Diabetes Mellitus: Channeling Care through Cellular Discovery
Current Neurovascular Research Adoptive Regulatory T-cell Therapy Attenuates Subarachnoid Hemor-rhage-induced Cerebral Inflammation by Suppressing TLR4/NF-B Signaling Pathway
Current Neurovascular Research Rho as a Target to Promote Repair: Translation to Clinical Studies with Cethrin
Current Pharmaceutical Design Neuropathic Pain and Lung Delivery of Nanoparticulate Drugs: An Emerging Novel Therapeutic Strategy
CNS & Neurological Disorders - Drug Targets Targeting Sarcomas: Novel Biological Agents and Future Perspectives
Current Drug Targets Characterization of Endogenous Neural Progenitor Cells after Experimental Ischemic Stroke
Current Neurovascular Research A Practical Comprehensive Approach to Management of Acute Decompensated Heart Failure
Current Cardiology Reviews Synthesis and Study of Analgesic and Anti-inflammatory Activities of Amide Derivatives of Ibuprofen
Mini-Reviews in Medicinal Chemistry A Review of Various Machine Learning Techniques for Brain Tumor Detection from MRI Images
Current Medical Imaging Cannabinoids and Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets (-)-Phenserine and Inhibiting Pre-Programmed Cell Death: In Pursuit of a Novel Intervention for Alzheimer’s Disease
Current Alzheimer Research The Urokinase Receptor in the Central Nervous System
CNS & Neurological Disorders - Drug Targets Biological Properties of Baicalein in Cardiovascular System
Current Drug Targets - Cardiovascular & Hematological Disorders Herpetic (Non-Cytomegalovirus) Retinal Infections in Patients with the Acquired Immunodeficiency Syndrome
Current HIV Research Multi-Modality Discrimination of Brain Glioma Grades Using Diffusion Tensor and Spectroscopic MRI
Recent Patents on Medical Imaging Aggressive Antioxidant Reductive Stress Impairs Brain Endothelial Cell Angiogenesis and Blood Brain Barrier Function
Current Neurovascular Research Disease-Induced Neuroinflammation and Depression
CNS & Neurological Disorders - Drug Targets Aflibercept (VEGF-TRAP): The Next Anti-VEGF Drug
Inflammation & Allergy - Drug Targets (Discontinued) Vasopressin-Receptor Antagonists: A New Class of Agents for the Treatment of Hyponatremia
Endocrine, Metabolic & Immune Disorders - Drug Targets Superior Neuroprotective Effects of Cerebrolysin in Nanoparticle-Induced Exacerbation of Hyperthermia-Induced Brain Pathology
CNS & Neurological Disorders - Drug Targets